

Time Table
Day 3, July 29 (Sat)

			7	8	9	10	11	12	13	14	15	16	17	18	19			
Kobe International Exhibition Hall	Kobe International Exhibition Hall	Room 1 (Portopia Hall)	South Building 1F			ISY14 Cancer Immunotherapy -What's the next?	EJ ESMO/JSMO Joint Symposium Optimal treatment for metastatic colorectal cancer (based on revised, latest ESMO, JSCCR treatment guideline)					SL5 Targeting immune regulation for cancer immunotherapy	EL21 Current medication for lung cancer	EL22 Updates in clinical development of immune checkpoint inhibitors				
		Room 2 (Convention Hall South)	Hall No.2 1F		WS13 The outcomes from nursing activities at the oncogenic outpatient unit		SY20 Adverse Event Management of Molecular Targeted Drugs by Interdisciplinary Medical Team Supportive Care which benefits Patients		MeS-29 The treatment strategy of NSCLC using anti-PD-1 antibody-How do we interpret the result of clinical trials to the clinical practice-?			SY21 Evidence & Practice: Outpatient Cancer Rehabilitation						
		Room 3 (Convention Hall North)	Hall No.2 1F			SY22 Multidisciplinary approach to cancer patients having complications		SY23 Clinical Pharmacology Studies of Tyrosine kinase inhibitors		MeS-30 Personalized treatment of non-small cell lung cancer, from cytotoxic agents, molecular targets to immunotherapy			SY24 Current status and problems of obtaining pharmaceutical approval and insurance coverage for multigene assay as a medical device					
		Room 4 (Hall A)	Hall No.1 2F		SPS Semi-Plenary Session		SY25 Discussing potential role of the clinical biobanks in early-phase clinical development		MeS-31 Recent Advances in Biology and Treatment of Myeloma Bone Disease			JS3 Joint Symposium 3 (JPOS/JSMO) Communication in cancer care and psychooncological support -The trajectory of the past decade and the near future-						
		Room 5 (Hall B)	Hall No.1 2F		O3-1 Lung Cancer 4 (Immunotherapy)	O3-2 Lung Cancer 5 (Molecular-targeted drug 1)	O3-3 Lung Cancer 6 (Molecular-targeted drug 2)	O3-4 Lung Cancer 7 (Molecular-targeted drug 3)		MeS-32 Reflecting on last 15 years - EGFR-TKI -			O3-5 Colorectal Cancer 3	O3-6 Colorectal Cancer 4				
		Room 6 (Conference Room 2A)	Hall No.2 2F	MoS-11 Concept of ICI treatment for NSCLC in the second line setting	O3-7 Esophageal Cancer	O3-8 Gastric Cancer 1	O3-9 Gastric Cancer 2	O3-10 Gastric Cancer 3		MeS-33 The role of second generation ALK-TKI in ALK+ NSCLC			SY26 Future prospects of treatments for advanced hepatocellular carcinoma					
		Room 7 (Conference Room 2B)	Hall No.2 2F	MoS-12 Considerations for sequencing of therapy for metastatic castration resistant prostate cancer						MeS-34 New therapeutic strategies of neuroendocrine tumor								
		Room 8 (Conference Room 3A)	Hall No.2 3F	MoS-13 The current trend of CRPC -the treatment strategy from biology and real world practice-	JS4 Joint Symposium 4 (JCS/JSMO) Cardio-Oncology - Future-oriented Cooperation between Cardiologist and Oncologist		SY27 Whereabouts of the Clinical Trial under the Clinical Research Act			MeS-35 Key drug of later line chemotherapy in metastatic colorectal cancer -Let's learn Regorafenib-			SL6 Molecular Genetics of Endometrial Carcinoma: The Past, Present and Future	WS14 Present and Future of ovarian cancer treatment				
		Room 9 (Conference Room 3B)	Hall No.2 3F	MoS-14 Diagnosis of myelodysplastic syndromes (MDS)	JS5 Joint Symposium 5 (JAPhMed/JSMO) Recent trends of Health Technology Assessment (HTA) in Japan		SY28 New developments for pathogenesis and treatment of MDS			MeS-36 The medical oncologist's past and future role in cooperative and adjuvant chemotherapy for gastric cancer								
Kobe International Conference Center (ICCK)	Kobe International Conference Center (ICCK)	Room 10 (Main Hall)	1F	EL23 Cancer survivorship research and care practices from a public health perspective	EL24 Evidence-based medicine in palliative care	EL25 Management of hepatitis B virus reactivation in cancer patients treated with systemic chemotherapy	EL26 Community-based supportive care for cancer patients at home	EL27 Rehabilitation for Cancer Patients	EL28 Support for families/caregivers of cancer patients	EL29 Acquired resistance to targeted drugs and novel therapy to overcome the resistance	EL30	MeS-37 Mechanisms of Endocrine Resistance in ER+ Breast Cancer	EL31 Upfront in drug therapy of advanced melanoma	EL32 Targeted therapy for cerebral metastasis	EL33 Understanding key issues of clinical trial articles in 30 minutes	EL34 Clinical pharmacology of older adult patients with cancer		
		Room 11 (International Conference Room)	3F	MoS-15 New treatment options of R/R PTCL	SL7 Future and Prospective Strategy for Follicular Lymphoma	ISY15 New therapeutic strategy for endocrine-refractory metastatic breast cancer				MeS-38 Follicular lymphoma - current standards of the ESMO guidelines		ISY16 Present and future status of hereditary cancer prophylactics						
		Room 12 (Reception Hall)	3F		WS15 Oligometastases	WS16 Particle Therapy: The creation of concrete evidence				MeS-39 Optimizing integration of genomics in cancer treatment approaches			SY29 Clinical pharmacology and therapeutics for cancer chemotherapy					
		Room 13 (501)	5F		O3-11 Gynecological Cancer	O3-12 Urologic Cancer	SY30 Treatment Strategy for Castration Resistant Prostate Cancer, 2017			MeS-40 Topics of palliative medicine / supportive care in medical oncology								
		Room 14 (502)	5F		SY31 Future perspectives of medical oncology and board-certified medical oncologists					MeS-41 Clinical questions and future perspective of immuno-oncology								
		Room 15 (504+505)	5F		SY32 Development of a genetic diagnostic education resource	O3-13 Anti Exposure Management	O3-14 Oncology Nursing			MeS-42 Precision medicine in Lung Cancer: New possibility of Crizotinib			O3-15 Team Medical Care 1	O3-16 Team Medical Care 2				
		Room 16 (503)	5F															
		Patient Advocate Program (401+402)	4F			PAP	PAP	PAP		PAP								
Kobe International Exhibition Hall	Kobe International Exhibition Hall	Poster Area	Hall No.3 1F		8:00-9:00 Poster Set-up				9:00-14:00 Poster Display			14:00-14:50 Poster Session	14:50-15:20 Poster removal					

Explanatory Notes

- EJ** =ESMO/JSMO Joint Symposium
- SPS** =Semi-Plenary Session
- JS** =Joint Symposium
- ISY** =International Symposium
- SY** =Symposium
- WS** =Workshop
- EL** =Educational Lecture
- SL** =Special Lecture
- MoS** =Morning Seminar
- MeS** =Medical Seminar
- ES** =Evening Seminar
- O** =Oral
- P** =Poster

I Simultaneous Interpretation (E&J)
E English Session
 ☘ Sponsored by Princess Takamatsu Cancer Research Fund

Closing Remarks